Guangzhou Royal Lee Cancer Center's Experienced Success in Yttrium-90 Liver Cancer Surgery

 

On April 24th, another yttrium-90 liver cancer surgery was successfully performed at the Nuclear Medicine Department of Royal Lee Cancer Center. The multidisciplinary team of experts in liver cancer yttrium-90 treatment at Royal Lee sequentially carried out successful transarterial injection of yttrium-90 resin microspheres for three liver cancer patients, achieving complete success in all three surgeries.

 

 

Director Niu Huimin is injecting yttrium-90 resin microspheres.

Dr. Niu Huimin, a renowned expert in yttrium-90 treatment in China and the lead surgeon for the first yttrium-90 resin microsphere liver cancer treatment, was invited to perform the surgeries for the patients.

 

The patient was a 71-year-old individual in stage IIIA of malignant liver tumor. After multiple rounds of assessment, discussions, and consultations by multidisciplinary experts, they underwent yttrium-90 microsphere treatment.

 

Preoperative Imaging Material

 

The multidisciplinary team of experts in liver cancer yttrium-90 treatment at Royal Lee comprises experts from various disciplines including Nuclear Medicine, Minimally Invasive Intervention, Hepatobiliary Surgery, and Oncological Surgery. To ensure the safety of the patients, Dr. Cao Mingrong, Dr. Niu Huimin, Dr. Liu Sheng, and other team experts conducted extensive research and held several multidisciplinary preoperative discussions regarding the patient's various indicators, ultimately formulating the treatment plan. The patient remained conscious throughout the procedure with stable vital signs, and their current recovery status is good.

 

Preoperative: MAA validation, patient meets Y90 surgery criteria.

 

Postoperative: Y90 microspheres deposited well within the tumor.